Navigation Links
InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
Date:3/7/2013

TEL AVIV, Israel, March 7, 2013 /PRNewswire/ --

InspireMD, Inc. (OTC: NSPR) (the "Company" or "InspireMD") filed an amended registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the resumption of a proposed underwritten public offering. Under the amended registration statement, the Company is offering $30 million worth of its shares of common stock.

In addition, InspireMD intends to grant the underwriters a 30-day option to purchase up to an aggregate of 15 percent additional shares of common stock to cover over-allotments, if any.

The Company intends to use the proceeds from the offering to support the worldwide commercialization of the MGuard™ Coronary in acute myocardial infarction, pursue FDA approval in the U.S., to redeem its convertible debentures, and for general corporate purposes.  

As part of the offering, the Company has applied to list its shares of common stock on the NYSE MKT.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

Cowen and Company, LLC is sole book runner and JMP Securities is acting as co-lead manager.  This offering shall be made only by means of a prospectus. Once available, a prospectus relating to these securities may be obtained from Cowen and Company, LLC (c/o Broadridge Financial Services) at 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling +1(631)274-2806.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under t
'/>"/>

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InspireMD Reports Results for Period Ended Dec. 31, 2012
2. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
3. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
4. InspireMD Reports Results For Period Ending Sept. 30, 2012
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD to Present at Harvard Investors Group on June 27 in New York
7. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
8. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
9. InspireMD Announces First Quarter 2012 Financial Results
10. Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2012
11. AUL Files Seventh Brief Supporting First Amendment Freedom of Conscience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 On the afternoon ... parent company of CPI International, Inc. (CPI), plans to ... July 3, 2015 with the Securities and Exchange Commission ... for the quarter.  At 11 a.m. (EDT) on Wednesday, ... call in conjunction with this release that will be ...
(Date:7/28/2015)... -- Research and Markets ( ... "Craniomaxillofacial Implants Market - Global Industry Analysis, ... 2022" report to their offering. ... the current and future prospects of the global ... the global market due to increasing facial deformities ...
(Date:7/28/2015)... 28, 2015 At the 2015 ... Association recognized 15 winners in the categories of ... across multiple vertical markets. ContextMedia:Health proudly took ... for its success with its first-to-market Patient ... ContextMedia:Health, the leading provider of digital solutions ...
Breaking Medicine Technology:CPI International To Announce Third Quarter 2015 Financial Results 2Global Craniomaxillofacial Implants (Plate and Screw Fixator Systems, Bone Graft Substitutes, Distraction Systems, and TMJ Replacement Devices) Market Analysis 2014-2022 2ContextMedia:Health Receives Top Award at the ICX Association Excellence Awards 2
... SPRING, Md., Oct. 24, 2011 The U.S. ... generic versions of Zyprexa (olanzapine tablets) and Zyprexa ... and bipolar disorder. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... and disabling brain disorder. About 1 percent of ...
... BRANFORD, Conn., Oct. 24, 2011 Clarient, a ... signed a definitive agreement to provide pharma services ... pharma clients.  By implementing HistoRx,s AQUA technology in ... their complementary capabilities to serve pharma companies, growing ...
Cached Medicine Technology:FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder 2FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder 3Clarient Joins the HistoRx® Clinical Trials Network: First Commercial Lab to Provide Aqua® Technology for Clinical Trials 2
(Date:7/28/2015)... ... July 28, 2015 , ... Dr. Aziz Ahmad recently gave a talk on ... noon to 1 p.m. Tuesday, June 23, at the Gulf Coast Regional Medical Center ... is board-certified in colorectal surgery and has more than 35 years of experience in ...
(Date:7/28/2015)... ... July 28, 2015 , ... Healthpointe ’s Cosmetic Laser ... skin to a smooth state, and reduces the appearance of fine lines and wrinkles. ... FDA-approved injectable gel to instantly add volume to your cheek area to correct age-related ...
(Date:7/28/2015)... ... ... to WFTV on July 15th heroin overdose rates have increased by 270 ... statistic Orlando suffers at least one death weekly as a direct result of a ... officials are struggling to keep apace with its distribution. Officers rely on inside information ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... targeted biologics and biologic-device combination products for the treatment of bone disorders and ... U.S. Patent No. 9,062,300 entitled "Fusion Proteins of Collagen Binding-Domain and Parathyroid Hormone". ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Women fear developing ... reason is that cancer, heart attack, and stroke are treatable, but there is little ... can do is to take part in a clinical trial, reports the July 2015 ...
Breaking Medicine News(10 mins):Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 2Health News:Heroin Overdose Deaths Increase by 270 Percent, Orlando Takes the Lead 3Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3
... Cardiovascular disease (CVD) death rates are declining, but CVD ... the United States, and risk factor control remains a ... from the American Heart Associations Heart Disease and Stroke ... available in the Dec. 17 online issue of Circulation: ...
... on an enzyme that is critical to the process ... target of antibacterial and anticancer drugs. Researchers with the ... Lab) and the University of California (UC) at Berkeley ... DNA-bound Type II topoisomerase (topo II) that is responsible ...
... for Dealing With Elderly Holiday Blues Offered by One of the ... ... of the country,s senior,healthcare experts from the world-renowned Los Angeles Jewish ... group,particularly vulnerable to the blues at this time of year -- ...
... CAMPAIGN "KICK ONE, PICK ONE" ENCOURAGING ... AND SPEND TIME TOGETHER, NEW YORK, Dec. 20 ... Nite announces the launch of "Kick One, Pick One",(KOPO), the ... fit and spend more time together. Bowing Jan. 1, KOPO ...
... children , , THURSDAY, Dec. 20 (HealthDay News) -- Holiday toys ... are threatening to cause more worry than joy. , Millions ... months by toy companies, many because they were decorated with ... Barbie, and Thomas the Tank Engine, among others. , The ...
... were given Nobel Direct dental implants, the risk of the ... at the Sahlgrenska Academy in Sweden shows that eight per ... was launched in 2004 by Nobel Biocare AB. The implants ... directly into the jawbone without having to first lift up ...
Cached Medicine News:Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 2Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 3Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 4Health News:Cardiovascular disease death rates decline, but risk factors still exact heavy toll 5Health News:First look at an enzyme target for antibacterial and cancer drugs 2Health News:First look at an enzyme target for antibacterial and cancer drugs 3Health News:First look at an enzyme target for antibacterial and cancer drugs 4Health News:It's Not Just About the Children 2Health News:It's Not Just About the Children 3Health News:Nick at Nite Asks Families to Kick a Bad Habit, Pick a Good One in 2008 2Health News:Nick at Nite Asks Families to Kick a Bad Habit, Pick a Good One in 2008 3Health News:Make Safe Toys Your Holiday Priority 2Health News:Make Safe Toys Your Holiday Priority 3Health News:Gloomy forecast for Nobel Direct after 3 years 2
... The ndigo OPTIMA Laser System is designed ... ablation using a near infrared laser source. ... the laser delivers a controlled level of ... to a temperature range where tissue necrosis ...
... a device intended for highly accurate measurements ... single most important metric for the diagnosis ... discovered in a large, randomized, five-year National ... mid-2002, the patients central cornea thickness (CCT) ...
Rapid Test Kit...
... Information System) is an open architecture system ... platform designed to communicate and manage patient ... be expanded in various ways, as NAVIS ... but also to fundus cameras and ophthalmic ...
Medicine Products: